Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenssa virus pinta-antigeenejä (haemagglutinin ja neuraminidaasin) kanta a, vietnam, 1194, 2004 (h5n1) - influenza, human; immunization; disease outbreaks - rokotteet - aktiivinen immunisaatio influenssa a -viruksen h5n1-alatyypin suhteen. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Suomi - suomi - Fimea (Suomen lääkevirasto)

zoetis animal health aps - equine influenza virus, a/1, newmarket 77, surface antigen, equine influenza virus, a/2, kentucky 98, surface antigen, equine influenza virus, a/2, borlange, surface antigen - injektioneste, suspensio - hevosen influenssavirus -rokote

Euroopan unioni - suomi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Euroopan unioni - suomi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Suomi - suomi - Fimea (Suomen lääkevirasto)

zoetis animal health aps - equine influenza virus, a/1, newmarket 77, surface antigen, equine influenza virus, a/2, borlange, surface antigen, tetanus toxoid, equine influenza virus, a/2, kentucky 98, surface antigen - injektioneste, suspensio - inaktivoitu hevosen influenssavirus -rokote + inaktivoitu klostridirokote

Suomi - suomi - Fimea (Suomen lääkevirasto)

intervet international b.v. - actinobacillus pleuropneumoniae opm antigen, actinobacillus pleuropneumoniae i toxoid, actinobacillus pleuropneumoniae ii toxoid, actinobacillus pleuropneumoniae iii toxoid - injektioneste, suspensio - actinobacillus/haemophilus rokote

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - influenssarokot - a (h1n1v) 2009 -viruksen aiheuttaman influenssan profylaksia. focetria-rokotetta tulee käyttää virallisen ohjeistuksen mukaisesti.

Euroopan unioni - suomi - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - rokotteet - active immunisation against h5 subtype of influenza a virus.

Suomi - suomi - Fimea (Suomen lääkevirasto)

laboratorios hipra s.a. - escherichia coli, lt toxoid, escherichia coli, f4a antigen, escherichia coli, f4ac antigen, escherichia coli, f5 antigen, escherichia coli, f6 antigen, clostridium perfringens beta toxoid, type c, clostridium novyi toxoid - injektioneste, suspensio

Suomi - suomi - Fimea (Suomen lääkevirasto)

aj vaccines a/s - corynebacterium diphtheriae toxoid, adsorbed, poliovirus type 1 (brunhilde), inactivated, poliovirus type 3 (saukett), inactivated, bordetella pertussis toxoid, adsorbed, poliovirus type 2 (mef-1), inactivated, clostridium tetani toxoid, adsorbed - injektioneste, suspensio - kurkkumätä-